Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:52 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,391 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Pill Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Opioid Analgesic Reduction Study

NCT04452344
View directory record Official record
Conditions
Opioid Use
Interventions
opioid-containing analgesic, two over-the-counter analgesics
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1,815 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 3, 2026, 1:52 PM EST
Withdrawn Not applicable Interventional

Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

NCT00682721
View directory record Official record
Conditions
Bacterial Vaginosis, Herpes Simplex Virus Type II
Interventions
Placebo, Valacyclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2012 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Nov 3, 2026, 1:52 PM EST
Completed Not applicable Interventional

Pain and Medication Use Following Surgery

NCT03179566
View directory record Official record
Conditions
Opioid Use
Interventions
Information Sheet, Deterra Drug Deactivation System
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Nov 3, 2026, 1:52 PM EST
Terminated Phase 3 Interventional Results available

Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

NCT02177266
View directory record Official record
Conditions
Atrial Fibrillation, Post-pericardiotomy Syndrome, Constriction
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2Phase 3 Interventional Results available

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

NCT02174419
View directory record Official record
Conditions
Prurigo Nodularis, Nodularis Prurigo, Prurigo, Pruritus
Interventions
nalbuphine HCl ER tablets 90 mg BID, nalbuphine HCl ER tablets 180 mg BID, Placebo tablets BID
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 3, 2026, 1:52 PM EST
Completed No phase listed Observational Results available

A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity

NCT05061472
View directory record Official record
Conditions
Contraceptive Usage, Overweight or Obesity, Body Weight Changes, Appetitive Behavior, Eating Behavior
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Timeline
2022 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 1Phase 2 Interventional Results available

Minocycline to Treat Branch Retinal Vein Occlusion

NCT01468831
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Minocycline, Placebo, Bevacizumab
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Ezetimibe on the Absorption of Oxidized Cholesterol

NCT00794677
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ezetimibe, placebo
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2 Interventional

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

NCT01549834
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ABT-126, placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Fresno, California • Long Beach, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Nov 3, 2026, 1:52 PM EST
Terminated Phase 3 Interventional Results available

Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries

NCT00935766
View directory record Official record
Conditions
Metabolic Diseases, Endocrine System Diseases, Heart Disease, Vascular Diseases, Diabetes, Cardiovascular Disease, Glucose Metabolism Disorders, Hypertension
Interventions
Omega-3, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2 Interventional Results available

FK506 (Tacrolimus) in Pulmonary Arterial Hypertension

NCT01647945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Placebo, FK506 level < 2 ng/ml, FK506 level 2-3 ng/ml, FK506 level 3-5 ng/ml
Drug
Lead sponsor
Edda Spiekerkoetter
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 1 Interventional Results available

Melatonin Use After Primary Total Joint Arthroplasty

NCT04795336
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Melatonin 5 mg, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 95 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 3 Interventional Results available

Study of Oral Fampridine-SR in Multiple Sclerosis

NCT00127530
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Nov 3, 2026, 1:52 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Strength Training and Resveratrol

NCT06585865
View directory record Official record
Conditions
Sarcopenia, Anabolic Resistance
Interventions
Resistance training, Resveratrol 500 mg oral once daily., Placebo
Behavioral · Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
60 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 1:52 PM EST
Recruiting Phase 2 Interventional

MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes

NCT06930638
View directory record Official record
Conditions
Stroke
Interventions
Ischemic Conditioning, Antioxidant Supplement
Device · Dietary Supplement
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Nov 3, 2026, 1:52 PM EST
Recruiting Phase 4 Interventional

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

NCT07136415
View directory record Official record
Conditions
Menopausal Women, Insomnia
Interventions
Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant
Behavioral · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • Novi, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Nov 3, 2026, 1:52 PM EST
Active, not recruiting Phase 4 Interventional

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Rosuvastatin, Colchicine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 3, 2026, 1:52 PM EST
Terminated Not applicable Interventional Results available

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

NCT02123576
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Pentoxyfylline, Placebo, AMO Therapy
Drug
Lead sponsor
Patrick Northup, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2Phase 3 Interventional Results available

The Effect of Milnacipran in Patients With Fibromyalgia

NCT01108731
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Perampanel on Neurophysiology Test Perimeters

NCT03653741
View directory record Official record
Conditions
Healthy
Interventions
Perampanel 6 MG
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 3, 2026, 1:52 PM EST
Completed Phase 2 Interventional Results available

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

NCT00632229
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Paliperidone, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
St. Petersburg, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Nov 3, 2026, 1:52 PM EST